Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma
- 101 Downloads
The clinical development and US Food and Drug Administration approval in 1997 of the monoclonal anti-CD20 antibody rituximab have been major treatment advances for patients with B-cell non-Hodgkin’s lymphoma (NHL). Rituximab produces responses in approximately 50% of cases of relapsed, low grade NHL. Most of these responses are partial remissions; cure remains elusive. One way to enhance the effectiveness of monoclonal antibodies is to chelate radionuclides such as yttrium-90 (90Y) to the antibody. 90Y is a high-energy, beta-emitting radioisotope that delivers most of its radiation over a path length of 2 to 5 mm. Therefore, the antibody delivers, or targets, the radiation only to CD20+ cells, sparing normal cells from the radiation. Ibritumomab is the murine anti-CD20 antibody that was engineered to develop the human chimeric antibody rituximab. Tiuxetan is a linker/chelator that is attached to the antibody to form ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA). Zevalin can be reacted with 111indium (111In) for imaging and 90Y for therapy. Phase I studies of Zevalin have determined that patients with a baseline platelet count greater than 150,000 × 106/L receive 0.4 mCi/kg. Patients with a platelet count of 100 to 149,000 × 106/L should receive 0.3 mCi/kg. Zevalin has a higher overall response rate (ORR) than its cold antibody counterpart rituximab, as demonstrated in two separate clinical trials. The first trial (IDEC 106-04) randomized 143 rituximab-naïve patients with relapsed NHL to receive rituximab or Zevalin. The ORR for Zevalin was 80% compared with 56% for rituximab (P = 0.002). The second trial (IDEC 106-06) tested the efficacy of Zevalin in patients who were rituxanrefractory; the ORR was 74%. The main toxicity of Zevalin was reversible myelosuppression. These studies indicate that radiolabeled anti-CD20 antibodies can produce a higher ORR than rituximab. Single-dose Zevalin is another treatment alternative for patients with relapsed low grade NHL. It is well-tolerated even by older adults. The exact role of Zevalin in the therapy of NHL is undetermined. New studies are underway to explore whether patients can safely receive a second dose of Zevalin and to combine Zevalin with highdose chemotherapy and stem cell rescue. The outcome of these studies will be helpful in deciding how best to integrate this new modality into the treatment paradigm of NHL.
KeywordsOverall Response Rate Peripheral Blood Stem Cell Transplant Tositumomab Ibritumomab Tiuxetan High Overall Response Rate
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 8.DeNardo SJ, DeNardo GL, Kukis DL, et al.: 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nuclear Med 1999, 40:302–310.Google Scholar
- 14.Press O, Eary J, Liu S, et al.: A phase I/II trial of high dose iodine-131anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas. Proc Am Soc Clin Oncol 1998, 17:3a.Google Scholar
- 19.Witzig T, Gordon L, Wiseman G, et al.: Reduced dose Zevalin is safe and effective in patients with relapsed or refractory low grade follicular or CD20+ transformed B cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Blood 2000, 96:728a.Google Scholar
- 20.Witzig Te, White Ca, Gordon L, et al.: Response to Zevalin is superior to response to rituximab regardless of age and extent of disease. Proc ASCO 2001, 20:279a.Google Scholar
- 21.Witzig T, White C, Flinn I, et al.: Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma. Blood 2000, 96:507a.Google Scholar
- 22.Witzig TE, Wiseman G: Clinical development of 90yttrium-conjugated murine anti-CD20 radioimmunoconjugates (90Y-ibritumomab tiuxetan, 90Y-Zevalin) for B-cell non-Hodgkin’s lymphomas. In Monoclonal Antibody Therapy of Hematologic Malignancies, edn 1. Edited by Cheson B. Abingdon, UK: Darwin Scientific Publishing Limited; 2001:203–214.Google Scholar